These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 38164178)
1. Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia. Sun J; Hu R; Han M; Tan Y; Xie M; Gao S; Hu JF Int J Biol Sci; 2024; 20(1):175-181. PubMed ID: 38164178 [TBL] [Abstract][Full Text] [Related]
2. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome. Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693 [TBL] [Abstract][Full Text] [Related]
3. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors. Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F; Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665 [TBL] [Abstract][Full Text] [Related]
4. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients. Wongboonma W; Thongnoppakhun W; Auewarakul CU Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255 [TBL] [Abstract][Full Text] [Related]
5. Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors. Yaghmaie M; Yeung CC Curr Hematol Malig Rep; 2019 Oct; 14(5):395-404. PubMed ID: 31463864 [TBL] [Abstract][Full Text] [Related]
6. Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition. Mitchell R; Hopcroft LEM; Baquero P; Allan EK; Hewit K; James D; Hamilton G; Mukhopadhyay A; O'Prey J; Hair A; Melo JV; Chan E; Ryan KM; Maguer-Satta V; Druker BJ; Clark RE; Mitra S; Herzyk P; Nicolini FE; Salomoni P; Shanks E; Calabretta B; Holyoake TL; Helgason GV J Natl Cancer Inst; 2018 May; 110(5):467-478. PubMed ID: 29165716 [TBL] [Abstract][Full Text] [Related]
7. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy. Ferri C; Bianchini M; Bengió R; Larripa I Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144 [TBL] [Abstract][Full Text] [Related]
8. Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study. Seman ZA; Ahid F; Kamaluddin NR; Sahid ENM; Esa E; Said SSM; Azman N; Mat WKDW; Abdullah J; Ali NA; Khalid MKNM; Yusoff YM BMC Res Notes; 2024 Apr; 17(1):111. PubMed ID: 38643202 [TBL] [Abstract][Full Text] [Related]
9. Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapy. Rodriguez J; Iniguez A; Jena N; Tata P; Liu ZY; Lander AD; Lowengrub J; Van Etten RA Elife; 2023 Apr; 12():. PubMed ID: 37115622 [TBL] [Abstract][Full Text] [Related]
10. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia. Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601 [No Abstract] [Full Text] [Related]
11. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance. Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of proteasomal deubiquitinases USP14 and UCHL5 overcomes tyrosine kinase inhibitor resistance in chronic myeloid leukaemia. Jiang L; He Q; Chen X; Liu A; Ding W; Zhang H; Chen X; Zhou H; Meng Y; Liu B; Peng G; Wang C; Liu J; Shi X Clin Transl Med; 2022 Sep; 12(9):e1038. PubMed ID: 36082692 [TBL] [Abstract][Full Text] [Related]
14. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928 [TBL] [Abstract][Full Text] [Related]
15. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386 [TBL] [Abstract][Full Text] [Related]
16. Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML). Wu J; Wang A; Li X; Chen C; Qi Z; Hu C; Wang W; Wu H; Huang T; Zhao M; Wang W; Hu Z; Liu Q; Wang B; Wang L; Li L; Ge J; Ren T; Xia R; Liu J; Liu Q Cancer Biol Ther; 2019; 20(6):877-885. PubMed ID: 30894066 [TBL] [Abstract][Full Text] [Related]
17. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy. Ali MA Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498 [TBL] [Abstract][Full Text] [Related]
18. Stem Cell Responsiveness to Imatinib in Chronic Myeloid Leukemia. Lahlil R; Aries A; Scrofani M; Zanetti C; Hennequin D; Drénou B Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068992 [TBL] [Abstract][Full Text] [Related]
19. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation. Egan DN; Beppu L; Radich JP Biol Blood Marrow Transplant; 2015 Jan; 21(1):184-9. PubMed ID: 25300870 [TBL] [Abstract][Full Text] [Related]
20. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]